Bcal Diagnostics Ltd has released a press release.
BCAL Enters US Product Development Agreement with Precion
Filed with ASX ·
6ix hasn’t read this filing yet.
BCAL Diagnostics Limited on 6ix
Earlier from BCAL Diagnostics
- Appendix 4D & Interim Report
- 7 February Announcement - Additional Information
- Recent Analysis Significantly Improves Commercial Prospects
- Dr John Hurrell Appointed Chief Executive Officer
- Strong Cohort 4 Testing Data Demonstrates Value of BCAL Test
Later from BCAL Diagnostics
- Breakthrough Results a Major Step Towards Commercialisation
- $2.4m Capital Raise to Further BREASTEST Commercialisation
- Preliminary Final Report
- Share Purchase Plan Offer Booklet
- Appointment of Strategic CEO to Lead Commercial Launch
Follow BCAL Diagnostics into a list and get an email when it puts out news.
Follow BCAL Diagnostics